Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Panel Supports Approval of Novo’s Long-Acting Insulin Despite Heart Concerns
FDAnews Drug Daily Bulletin
Nov. 12, 2012 | Vol. 9 No. 222
FDA Panel Supports Approval of Novo’s Long-Acting Insulin Despite Heart Concerns
FDA advisers voted 8–4 Thursday in support of approval for Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg for Type 1 and Type 2 diabetes despite lingering worries about cardiovascular effects. The Endocrinologic and Metabolic Drugs Advisory Committee also voted unanimously in favor of requiring a cardiovascular outcomes trial with Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart). Panelists split on whether the trial should be conducted in the pre- or postmarket setting.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.